Foresite’s James Tananbaum acquires 140,000 Latigo Biotherapeutics shares for $2.52 million

• Latigo Biotherapeutics director James B. Tananbaum reported acquiring 3,562,984 shares of common stock through Foresite Capital Fund V.
• Foresite Capital Fund VI reported holdings rising to 2,203,800 shares, including a 140,000-share purchase at USD 18.
• Foresite Capital Opportunity Fund V reported holdings increasing to 3,414,544 shares of common stock.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Latigo Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001581754-26-000006), on August 10, 2026, and is solely responsible for the information contained therein.